家族性HDL欠乏症におけるABC1遺伝子の変異と,欠陥コレステロール流出の異常
M Marcil1, A Brooks-Wilson, S M Clee
1Xenon Bioresearch Inc, NRC Innovation Centre, Vancouver, British Columbia, Canada.
Lancet (London, England)
|October 26, 1999
まとめ
ATP結合カセット (ABC1) 遺伝子の変異は,細胞のコレステロール流出を損なうことで,家族性高密度リポタンパク質 (HDL) 欠乏を引き起こす. これは,ABC1調節が,HDLレベルを上昇させるための潜在的な戦略であることを強調しています.
科学分野:
- 遺伝学と分子生物学について
- 心血管研究 循環器科の研究
- メタボリック障害 メタボリック障害
背景:
- 低高密度脂質タンパク質 (HDL) コレステロールは,早発性動脈硬化で一般的です.
- タンジャール病は,重度のHDL欠乏症であり,コレステロール流出調節タンパク質 (CERP) をコードするATP結合カセット (ABC1) 遺伝子の変異によって引き起こされる.
研究 の 目的:
- 家族性HDL欠乏症の患者におけるABC1遺伝子の変異を調査する.
主な方法:
- 遺伝的なHDL欠乏症を持つフランス系カナダ人3家族とオランダ人1家族を調査した.
- 線維細胞のコレステロール流出を分析し,ABC1遺伝子のコーディング領域をシーケンス化しました.
- 遺伝子変異を家族内および対照群で追跡するためにPCRおよびRFLPアッセイを使用した.
主要な成果:
- それぞれのファミリーで,CERPの断片化または改変されたアミノ酸残留につながる,明確なABC1変異を特定しました.
- 特定されたすべての変異は,低レベルのHDLコレステロールと分離した.
- 500以上のコントロール染色体では突然変異は見つかりませんでした.
結論:
- ABC1変異は,障害のあるコレステロール流出に関連した家族性HDL欠乏の主要な原因です.
- CERPは,HDL形成において重要な役割を果たします.
- ABC1の調節は,HDL濃度を高めるための潜在的な治療方法を提供します.
関連する概念動画
ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
ABC Transporters: Importer
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


